Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 111.14% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 111.14% YoY), and the FY2025 full-year result was $1.5 million, down 44.3% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $3.0 million, up from $1.5 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $3.0 million in Q1 2026, with the low at $711000.0 in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $1.6 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 59.3% — and 2023, when it soared 152.74%.
• Barinthus Biotherapeutics' Other Non-Current Liabilities stood at $965000.0 in 2022, then surged by 37.31% to $1.3 million in 2023, then surged by 100.0% to $2.6 million in 2024, then plunged by 44.3% to $1.5 million in 2025, then soared by 100.27% to $3.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.